Amyvid (Florbetapir F 18 injection) is a radioactive agent for PET imaging of the brain in adults to estimate the brain amyloid plaque content in patients who have cognitive decline. The medicine was approved for use by the FDA. Cognitive decline is a situation where a patient has difficulty thinking clearly and rationally and making decisions. This makes the individual lose touch with reality, themselves, others and events, and surroundings around them.
Clinicians use Amyvid to detect Alzheimer’s disease early and also accurately identify patients who show early signs of memory impairments. Amyvid as a radioactive agent tags the β-amyloid proteins, which are hallmarks of Alzheimer’s disease. PET scans are used to detect the β-amyloid protein which also forms in other cognitive disorders.
Notable facts on Amyvid PET Scan:
- A negative scan is when there are few or no amyloid plaques or neuritic plaques detected. This means that the cognitive decline in the patient is not due to Alzheimer’s disease.
- A positive scan shows average to persistent plaques, meaning that the patient is likely to have Alzheimer’s disease as well as other cognitive impairments. A positive scan can also show in normal cognitive patients. The FDA insists that a positive scan doesn’t mean the presence of Alzheimer’s, but all patients with Alzheimer’s disease have a plaque content that is higher.
- Before, the brain content of β-amyloid neuritic plaques was determined using a brain biopsy or through examining the brain during autopsy. Amyvid with PET scan helps physicians to assess their patients by serving as an accessory to many other diagnostic evaluations.
- Florbetapir provides more information regarding amyloid plaques that could be present in the brain. This is an advancement in the practice of nuclear medicine since it necessitates the evaluation of the absence or presence of average to persistent amyloid plaque levels in the brain of a patient. Alongside other tests, florbetapir can assist physicians by providing extra information during patient evaluation to determine the cause of the cognitive decline.
The FDA says that Amyvid PET scan cannot substitute the existing diagnostic tests for cognition evaluation. Neither does the scan predict the development of Alzheimer’s disease or other associated dementia, nor does it monitor the way patients respond to treatments. The side effects connected to using Amyvid include musculoskeletal pain, fatigue, nausea, and headache.